Biological Evaluation of a Novel Angiotensin II AT1 Receptor Antagonist with Anti-Hypertensive and Anti-Tumor Effects

A novel nonpeptide angiotensin II receptor 1 antagonist, compound 1, N-butyryl-N-[(2'-(2, 5-dihydro-5-oxo-1, 2, 4-oxadiazol-3-yl) biphenyl-4-yl) methy-L-Valine was investigated by receptor-binding studies and vivo experiments in spontaneously hypertensive rats and renal hypertensive rats. Furthermore, treatment with compound 1 significantly inhibited the viability of human breast cancer cell line and promoted apoptosis of the cancer cells. The compound had the effects of anti-hypertension and anti-cancer, which suggested that this new compound could be considered as a candidate for both novel anti-hypertensive and anti-cancer agent.